2023 World Conference on Lung Cancer (Posters)-EP12.01. Tepotinib and Capmatinib in Patients with MET exon 14 Skipping NSCLC: A Matching Adjusted Indirect Comparison (MAIC)

EP12.01. Tepotinib and Capmatinib in Patients with MET exon 14 Skipping NSCLC: A Matching Adjusted Indirect Comparison (MAIC) - PDF(Abstract)

Back to course

Pdf Summary

This study conducted a matching-adjusted indirect comparison (MAIC) between two tyrosine kinase inhibitors, Tepotinib and Capmatinib, in patients with MET exon 14 skipping non-small cell lung cancer (NSCLC). Tepotinib and Capmatinib have been approved for the treatment of MET exon 14 skipping NSCLC based on non-randomized Phase II trials. Previous MAIC results predicted better progression-free survival (PFS) and overall survival (OS) with Tepotinib compared to Crizotinib and Capmatinib. <br /><br />The updated MAIC analysis included Tepotinib outcomes from a larger patient population in the VISION trial with a later data cut-off. Patients from the VISION trial were reweighted to match the baseline characteristics of patients in the GEOMETRY mono-1 trial receiving Capmatinib. The analysis compared objective response rate (ORR), PFS, and OS between Tepotinib and Capmatinib in treatment-naïve (1L) and previously treated (2L) patients with MET exon 14 skipping advanced NSCLC.<br /><br />In the matched 1L population, Tepotinib had an ORR of 59.9% and appeared to be associated with prolonged PFS and OS compared to Capmatinib. In the matched 2L population, Tepotinib had an ORR of 50.1% and also appeared to be associated with prolonged PFS and OS compared to Capmatinib.<br /><br />The updated data from the VISION trial improve the robustness of the MAIC analysis and confirm previous findings of better PFS and OS with Tepotinib compared to Capmatinib. However, caution should be exercised in interpreting the results due to possible unobserved confounders. The MAIC data provides valuable information in the absence of head-to-head trials, and the analysis will be further updated as new data becomes available from ongoing studies.

Asset Subtitle

Boris Pfeiffer

Meta Tag

Speaker Boris Pfeiffer

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

matching-adjusted indirect comparison

tyrosine kinase inhibitors

Tepotinib

Capmatinib

MET exon 14 skipping non-small cell lung cancer

non-randomized Phase II trials

progression-free survival

overall survival

VISION trial

GEOMETRY mono-1 trial